12:22:48 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Oncopeptides är ett läkemedelsbolag som bedriver forskning och utveckling av cancerläkemedel. Sedan starten fokuserar bolaget främst på den egenutvecklade produkten Ygalo, en alkylerare för behandling av blodbaserade cancersjukdomar. Till kategorin räknas bland annat kronisk leukemi, lymfom och myelom. Bolaget är i utvecklingsfas där målet är att kommersialisera produkten i framtiden. Oncopeptides huvudkontor är beläget i Stockholm.

Kalender

2020-11-19 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning ONCO 0.00 SEK
2020-05-26 Årsstämma 2019
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-12-17 Extra Bolagsstämma 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-05-22 Ordinarie utdelning ONCO 0.00 SEK
2019-05-21 Kvartalsrapport 2019-Q1
2019-05-21 Årsstämma 2018
2019-02-22 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-13 Kvartalsrapport 2018-Q2
2018-05-18 Ordinarie utdelning ONCO 0.00 SEK
2018-05-17 Kvartalsrapport 2018-Q1
2018-05-17 Årsstämma 2017
2018-02-22 Bokslutskommuniké 2017
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-18 Kvartalsrapport 2017-Q1
2017-05-18 Årsstämma 2016
2020-02-20 08:00:00

Summary

Financial overview October 1 - December 31, 2019
  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 244,9 M (loss: 112.0)
  • Loss per share, before and after dilution, was SEK 4.42 (loss: 2.54)
  • On December 31 cash and cash equivalents amounted to SEK 926.2 M (375.6)
Significant events during the period October 1 - December 31, 2019
  • In early December, an advisory meeting was held with the FDA is preparing for Oncopeptides'application for accelerated market approval
  • At the annual American Hematology Meeting (ASH) in December, Oncopeptides presented updated efficacy and safety data from the pivotal phase 2 study HORIZON in RRMMnpatients and promising data from the phase 2 combination study ANCHOR
  • At the ASH meeting it was also presented preclinical data regarding melflufen for AL amyloidosis, which forms the basis for the clinical program where the patient recruitment has started
  • In the process of preparing for a potential launch in the United States, Joseph Horvat was appointed as President North America
  • At an Extraordinary General Meeting in December, it was resolved to issue warrants and to extend the board's authorization to issue shares

Financial overview of the group

[][]
SEK thousand 2019 2018[1)] 2019 2018[1)]
Oct - Dec Oct - Dec Jan - Dec Jan - Dec
Net sales   -  -  - -
Operating loss   -244,244 -111,859 -739,392 -410,963
Loss before tax   -244,400 -111,861 -739,392 -410,965
Loss for the period -244,904 -112,008 -740,705 -411,112
 
Earnings per share -4.42 -2.54 -14.33 -9.58
before and
after dilution (SEK)
 
Cash flow from -216,974 -108,855 -690,566 -333,727
operating activities
 
Cash and cash 926,186 375,617 926,186 375,617
equivalents
at the end of the
period             
Research & 64%  81% 74%  76%
development costs/
Operating expenses %
                    

1) Earlier periods have been adjusted to reflect correction of errors, see note 7.

Conference call for investors, analysts and the media
The Interim Report Q4 2019 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Thursday February 20, 2020 at 14.00 (CET).

The conference call will also be streamed via a link on the website: www.oncopeptides.com

Phone numbers for participants from:
Sweden: +46 8 505 583 56
Europe: +44 3333 009 031
USA: +1 833 526 83 82

Financial calendar
Interim Report Q1, 2020: May 26, 2020
Annual General Meeting May 26, 2020
Interim Report Q2, 2020: August 26, 2020
Interim Report Q3, 2020: November 19, 2020

For further information
Jakob Lindberg, CEO, Oncopeptides AB
E-mail: jakob.lindberg@oncopeptides.com
Telephone: +46 (0)8 615 20 40

Rein Piir, Head of Investor Relations, Oncopeptides AB
E-mail: rein.piir@oncopeptides.com
Telephone: +46 (0)70 853 72 92

This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on February 20, 2020.

About Oncopeptides
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers. The company is focusing on the development of the lead product candidate melflufen, a first-in-class peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in four clinical trials including the pivotal Phase 2 HORIZON trial and the ongoing Phase 3 OCEAN trial. Oncopeptides' headquarters is in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

For more information please visit www.oncopeptides.com.